TET2 and acute myeloid leukemia: Our data demonstrate that single-agent 5′-Aza treatment of AML harboring biallelic TET2 mutations can give rise to long-term CR, including disease otherwise refractory to standard 3+7 induction chemotherapy with daunorubicin and Ara-C and in patients with adverse-risk disease or poor performance status.